Camilla Petrycer Hansen, PhD
Camilla is a principal in Novo Holdings, where she is responsible for company creation and early investments as well as investments focused on anti-infectives under the REPAIR Impact Fund. Prior to joining Novo Holdings, Camilla spent 10 years in business development across academia, start-ups and industry. Camilla currently serves on the board of directors of Centauri and Hoba Therapeutics, and is an observer in Muna Therapeutics, Hemab and Acesion.
Camilla has a PhD in Medicinal Chemistry and a Master of Pharmacy degree from Copenhagen University.